Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators..

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797.

2.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators..

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
3.

Coronary artery slow flow associated with angina pectoris and hypotension--a case report.

Burckhartt BA, Mukerji V, Alpert MA.

Angiology. 1998 Jun;49(6):483-7.

PMID:
9631895
4.

Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits.

Burckhartt B, Yang XM, Tsuchida A, Mullane KM, Downey JM, Cohen MV.

Cardiovasc Res. 1995 May;29(5):653-7.

PMID:
7606753
5.

Acadesine extends the window of protection afforded by ischaemic preconditioning.

Tsuchida A, Yang XM, Burckhartt B, Mullane KM, Cohen MV, Downey JM.

Cardiovasc Res. 1994 Mar;28(3):379-83.

PMID:
8174159

Supplemental Content

Loading ...
Support Center